Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Javier Cortes comments on study results in neoadjuvant triple negative breast cancer setting.
He first talks about improved PFS in patients with CPS ≥10 PD-L1 positive tumours demonstrated in the KEYNOTE-355 trial which tested addition of pembrolizumab to chemotherapy for previously untreated locally recurrent, inoperable or metastatic triple negative breast cancer. Secondly he discusses the results of molecular profiling in the ARTEMIS platform and the use of enzalutamide in patients with androgen receptor-positive triple negative breast cancer.
Abstracts:
- 1000: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer - Javier Cortes
- 517: Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide - Boram Lim
This video was supported with an educational grant from Daiichi Sankyo and Novartis. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.